Cardiovascular outcome trials (CVOTs) have consistently demonstrated that GLP-1 RA reduce the risk of major adverse cardiovascular events (MACE), particularly nonfatal myocardial infarction and stroke (66, 67). The gene discussed is GLP1R; the disease is stroke disorder.